Colorectal cancer (CRC) is a leading global cause of illness and death. There is a need for identification of better prognostic markers beyond traditional clinical variables like grade and stage. Previous research revealed that abnormal expression of cytokeratin 7 (CK7) and loss of the intestinal-specific Special AT-rich sequence-binding protein 2 (SATB2) are linked to poor CRC prognosis. This study aimed to explore these markers' prognostic significance alongside two extraintestinal mucins (MUC5AC, MUC6), claudin 18, and MUC4 in 285 CRC cases using immunohistochemistry on tissue microarrays (TMAs). CK7 expression and SATB2-loss were associated with MUC5AC, MUC6, and claudin 18 positivity. These findings suggest a distinct "non-intestinal" immunohistochemical profile in CRC, often right-sided, SATB2-low, with atypical expression of CK7 and non-colorectal mucins (MUC5AC, MUC6). Strong MUC4 expression negatively impacted cancer-specific survival (hazard ratio = 2.7, p = 0.044). Genetic analysis via next-generation sequencing (NGS) in CK7 + CRCs and those with high MUC4 expression revealed prevalent mutations in TP53, APC, BRAF, KRAS, PIK3CA, FBXW7, and SMAD4, consistent with known CRC mutation patterns. NGS also identified druggable variants in BRAF, PIK3CA, and KRAS. CK7 + tumors showed intriguingly common (31.6%) BRAF V600E mutations corelating with poor prognosis, compared to the frequency described in the literature and databases. Further research on larger cohorts with a non-colorectal immunophenotype and high MUC4 expression is needed.

Central Laboratories University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Anaesthesia and Intensive Care Medicine 3rd Faculty of Medicine Charles University University Hospital Kralovske Vinohrady Prague Czech Republic

Department of General Surgery 3rd Faculty of Medicine Charles University University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Pathology 1st Faculty of Medicine Charles University General University Hospital Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University University Hospital Kralovske Vinohrady Šrobárova 1150 50 Praha 10 10034 Prague Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University Thomayer University Hospital Prague Czech Republic

Zobrazit více v PubMed

Morgan, E. PubMed DOI

Sung, H. PubMed DOI

Hrudka, J., Fišerová, H., Jelínková, K., Matěj, R. & Waldauf, P. Cytokeratin 7 expression as a predictor of an unfavorable prognosis in colorectal carcinoma. PubMed DOI PMC

Hrudka, J. PubMed DOI PMC

Shanmugam, C. PubMed DOI PMC

Kubota, Y. PubMed DOI PMC

Hrudka, J. PubMed DOI PMC

Erlenbach-Wünsch, K. Histomorphologische und molekularpathologische Prognosefaktoren beim kolorektalen Karzinom. PubMed DOI

Eberhard, J. PubMed DOI PMC

Kim, C. J. PubMed DOI

Imai, Y. PubMed DOI PMC

Betge, J. PubMed DOI PMC

Kocer, B. PubMed DOI

Wang, H. PubMed DOI PMC

Cox, K. E. PubMed DOI PMC

Bartman, A. E. PubMed DOI

Owens, S. R., Chiosea, S. I. & Kuan, S. F. Selective expression of gastric mucin MUC6 in colonic sessile serrated adenoma but not in hyperplastic polyp aids in morphological diagnosis of serrated polyps. PubMed DOI

Leir, S. H. & Harris, A. MUC6 mucin expression inhibits tumor cell invasion. PubMed DOI

Sanada, Y. PubMed DOI

Kyuno, D. PubMed DOI PMC

Sentani, K. PubMed DOI

Ungureanu, B. S. PubMed DOI PMC

Arpa, G. PubMed DOI PMC

Matsuda, M. PubMed DOI

Moniaux, N. PubMed DOI PMC

Chaturvedi, P., Singh, A. P. & Batra, S. K. Structure, evolution, and biology of the MUC4 mucin. PubMed DOI PMC

Chaturvedi, P. PubMed DOI PMC

Miyahara, N. PubMed DOI

Komatsu, M., Jepson, S., Arango, M. E., Carothers Carraway, C. A. & Carraway, K. L. Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. PubMed DOI

Chaturvedi, P. PubMed DOI

Biemer-Hüttmann, A. E. PubMed

Pai, P. PubMed DOI PMC

Huang, X. PubMed PMC

Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. PubMed DOI

Pino, M. S. & Chung, D. C. The chromosomal instability pathway in colon cancer. PubMed DOI PMC

Müller, M. F., Ibrahim, A. E. & Arends, M. J. Molecular pathological classification of colorectal cancer. PubMed DOI PMC

Wood, L. D. PubMed DOI

Zhuang, Y. PubMed DOI PMC

Liu, Z. PubMed DOI PMC

Network, C. G. A. Comprehensive molecular characterization of human colon and rectal cancer. PubMed DOI PMC

Al-Shamsi, H. O. PubMed DOI PMC

Hino, H. PubMed DOI

Oncokb.org. (accessed 19th Mar 2024).

Chen, D. PubMed DOI PMC

Li, Y. & Li, W. BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis. PubMed DOI PMC

Toon, C. W. PubMed DOI PMC

Loupakis, F. PubMed DOI PMC

Varkaris, A. PubMed DOI PMC